|
Distribution Plan Begins for Outpatient Bamlanivimab Treatment of COVID-19
|
|
Just because the FDA approves a COVID-19 therapy doesn’t mean anyone can get it. Pharmacists should be aware that a federal/state distribution plan will determine availability of the investigational monoclonal antibody therapy bamlanivimab for mild-to-moderate novel coronavirus infection. Here is how it works.
|
|
|
Empagliflozin Also Beneficial in Heart-Failure Patients
Without Diabetes
|
|
|
A drug developed to treat type 2 diabetes now shows benefit for improving heart failure with reduced ejection fraction in nondiabetics. Find out what effect empagliflozin had on patients with normal blood sugar and HFrEF, and why researchers think their results will be practice-changing.
|
|
More Than a Million U.S. Children Have Tested Positive for COVID-19
|
|
|
Children generally have mild or no symptoms when infected with COVID-19, but that doesn’t mean they aren’t contracting the infection at high rates. A survey by the American Academy of Pediatrics and the Children’s Hospital Association reports that more than a million children now have tested positive for novel coronavirus, based on state data. Here are more details.
|
|
|
Statin ‘Side Effects’ Also Tend to Occur When Patients Are
Taking a Placebo
|
|
Pharmacists often hear complaints about statin side effects and are dealing with patients seeking to discontinue the cholesterol-lowering drugs. A new study suggests, however, that most of those concerns are the “nocebo effect,” where side effects from a therapy are experienced because of a negative association with it instead of actual pharmacologic action. Here is more information.
|
|
